Viaskin Peanut Patch

Indicated For

peanut allergy

About This Medication

# Viaskin Peanut Patch Patient Guide: How to Get Viaskin Peanut Patch at Low or No Cost **Important Note:** As of March 2026, the Viaskin Peanut Patch from DBV Technologies is not yet FDA-approved and remains in late-stage clinical development. DBV plans to submit a Biologics License Application (BLA) in the first half of 2026, with potential approval for children aged 4-7 (and possibly younger) later this year. No commercial patient assistance program exists at this time because the patch is investigational. This guide provides information on current access options like clinical trials and expanded access, what to expect post-approval, and steps to prepare. Always consult your allergist for personalized advice. ## About the Viaskin Peanut Patch The **Viaskin Peanut Patch** is a needle-free, daily-wear skin patch designed for epicutaneous immunotherapy (EPIT). It delivers a tiny, controlled dose of peanut protein (250 micrograms) through intact skin to help desensitize the immune system in children with peanut allergy. Unlike oral treatments, it avoids swallowing allergens, reducing gastrointestinal side effects.[1][3][8] **Key Benefits from Clinical Trials:** - In the Phase 3 VITESSE trial (children 4-7 years), 46.6% of patch users met desensitization criteria after 12 months (tolerating more peanut protein), vs. 14.8% on placebo.[3][4] - Long-term data from the PEOPLE extension study showed sustained benefits: over 73% response rate after 5 years, with high compliance (93%).[7] - Targets ages 1-11, with ongoing trials for toddlers (1-3 years) under FDA accelerated approval pathway.[5][6] Peanut allergy affects millions, causing risks of severe reactions or anaphylaxis. Viaskin aims to provide a safer daily life by building tolerance to accidental exposure.[1] ## Who Qualifies for Access? **Currently (Pre-Approval):** Access is limited to clinical trials or Expanded Access Program (EAP). - **Clinical Trials:** Open to peanut-allergic children meeting criteria (e.g., ages 1-7+). Recent VITESSE trial enrolled 654 children; check clinicaltrials.gov for ongoing studies like NCT05741476.[9] - **Expanded Access:** DBV offers EAP for patients unable to join trials but with serious need. Contact DBV directly.[2] **Post-Approval Expectations:** Patient assistance programs (PAPs) from manufacturers like DBV typically help uninsured or underinsured patients. Since details are unavailable now (null program data), expect eligibility based on: - U.S. residency. - Household income at or below **400-500% Federal Poverty Level (FPL)** (common threshold; e.g., $60,000+ for family of 4). - Prescription from a licensed provider. ## Income Eligibility Breakdown No specific thresholds published yet. Here's a general table for similar allergy PAPs (e.g., Palforzia). DBV's may align post-approval: | Household Size | 400% FPL Example | 500% FPL Example | Notes | |---------------|------------------|------------------|-------| | Individual | $58,320 | $72,900 | Annual income | | Couple | $78,880 | $98,600 | +$20,560 per additional member | | Family of 3 | $99,440 | $124,300 | Varies by program | | Family of 4 | $120,000 | $150,000 | Assets may count | *Table based on 2026 FPL estimates; confirm with DBV post-launch. Programs often exclude high assets or certain insurance.*[General knowledge] ## Insurance Requirements **Pre-Approval:** Trials/EAP may cover costs; insurance not always required. **Post-Approval:** Likely requires commercial insurance denial first (government insurance like Medicare/Medicaid often ineligible). DBV may offer copay cards for insured patients ($0-$10 copays). Uninsured get free meds via PAP.[General PAP standards] ## Step-by-Step Application Process **For Current Access (Trials/EAP):** 1. Consult your allergist to confirm peanut allergy diagnosis (skin/blood tests). 2. Search clinicaltrials.gov for Viaskin studies (e.g., "DBV712" or "Viaskin Peanut").[9] 3. Contact DBV: Visit dbv-technologies.com or email for EAP.[2] 4. Submit medical records, allergy history. **Post-Approval PAP (Projected):** 1. Get prescription from allergist. 2. Apply online/phone (details TBA; likely dbv-technologies.com/pap). 3. Upload/provide: Proof of income (tax returns), insurance denial, ID, prescription. 4. Doctor may need to enroll patient. 5. Approval in 1-4 weeks; meds shipped free. ## Timeline and Delivery - **Trials:** Varies; some immediate start. - **EAP:** Case-by-case. - **PAP (Expected):** Processing 2-4 weeks. Annual re-enrollment. Free home delivery via mail.[General] Patches worn daily on upper arm/back for 24 hours, rotated sites. ## Alternatives if Denied or Ineligible - **Other Immunotherapies:** Palforzia (oral; FDA-approved, has PAP via Aimmune).[5] - **Trials:** Ongoing Viaskin studies.[1][4] - **Biosimilars/Generics:** None yet (novel biologic).[ ] - **Manage Allergy:** EpiPen, strict avoidance, allergy specialist. - **State Programs:** Check for allergy aid. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Viaskin Peanut Patch is investigational; efficacy/safety not FDA-confirmed. Consult healthcare provider. Program details may change upon approval. DBV not liable for guide content. Word count: ~950.

Program information last verified: March 30, 2026